XHKG
2877
Market cap706mUSD
Oct 09, Last price
7.43HKD
1D
1.23%
1Q
-3.13%
Jan 2017
-15.57%
IPO
58.09%
Name
China Shineway Pharmaceutical Group Ltd
Chart & performance
P/E
5.04
P/S
1.53
EPS
1.26
Div yield, %
6.88%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
3.38%
Revenues
3.14b
-17.01%
Net income
950m
+13.08%
CFO
1.17b
+21.69%
Dividend
Oct 02, 20260.995 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As an investment holding company, China Shineway Pharmaceutical Group Limited primarily focuses on the research, development, production, and commercialization of traditional Chinese medicines across mainland China and Hong Kong. Its product portfolio encompasses contemporary Chinese medicines delivered as soft capsules, granules, and injectable solutions. Additionally, it provides specialized TCM Formula Granules, addressing a broad spectrum of medical conditions such as cardiovascular and cerebrovascular issues, viral infections, orthopedic complaints, pediatric ailments, gynecological disorders, and gastrointestinal problems. Beyond pharmaceuticals, the group also engages in the trading of agricultural commodities. Established in 2004, China Shineway Pharmaceutical Group Limited maintains its corporate headquarters in Shijiazhuang, within the People's Republic of China. The company operates as a subsidiary under the umbrella of Forway Investment Limited.
Key people
Guozhi Jiang
Vice President · since 2023
Bun Ching Lee
Financial Controller, Company Secretary · since 2017
Zhenjiang Li
Executive Chairman of the Board · since 2018
Huimin Li
Executive Director
Yunxia Xin
Executive Director
King Kuen Hung
Director of Investor Relation · since 2017
Tiejun Liu
Vice President of Shineway Pharmaceutical Group Limited · since 2023
Wencheng Zhou
Non-Executive Director · since 2020
Independent Non-Executive Director · since 2021
Guihua Wang
Independent Non-Executive Director · since 2023
Yat On Yew
Independent Non-Executive Director · since 2022
Headquarters & legal address
c/o CONYERS TRUST COMPANY (CAYMAN) LIMITED, Cricket Square, Hutchins Drive, P.O. Box 2681
Grand Cayman KY1-1111
KY
Grand Cayman KY1-1111
KY
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||